Indiana University School Of Medicine

The IVBM event discussed future oncology, focusing on personalized care, patient education, and collaboration. Experts explored immunotherapy advancements, HER2-targeted therapies, predictive biomarkers, and pharmacy decision-making. Key topics included immunotherapy evolution, lung cancer screening, emerging technologies, antibody-drug conjugates, disparities in molecular testing, and the need for education and collaboration to improve outcomes.

Depletion of GCN2 and loss of p53 enhances prostate cancer cell death, suggesting a novel therapeutic strategy targeting GCN2 and p53 signaling.

Galectin Therapeutics' stock dropped 35% after its lead asset, Belapectin, failed to reach the primary endpoint in a Phase IIb/III trial for MASH cirrhosis. While Belapectin reduced varices incidence by 48.9% in the per-protocol population, it fell short of the 52.5% target. The drug showed a highly encouraging safety profile and potential in advanced melanoma. Galectin plans to analyze 36-month outcomes before determining next steps.

Purdue University and Indiana University School of Medicine researchers received a $1.5 million grant to develop a noninvasive device for monitoring autonomic dysreflexia, a condition affecting spinal cord injury patients. The device, tested with 94.1% accuracy in humans, uses sensors to detect AD and can be integrated into wearable technology for continuous home monitoring.

PDS Biotechnology announces a Key Opinion Leader event on Dec 17, 2024, to discuss HPV16-positive HNSCC and the VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab. Panelists include Dr. Francis Worden and Dr. Kevin Harrington, moderated by Dr. Kirk Shepard.

Foundation Fighting Blindness, in partnership with ARPA-H, aims to achieve vision recovery through six whole eye transplants in humans by 2030, with a $46 million grant supporting a multi-disciplinary consortium led by the University of Colorado Anschutz Medical Campus.

Podcast with Molecular Devices features Dr Milan Radovich, SVP & CSO at Caris Life Sciences, and Yochi Slonim, co-founder & CEO of Anima Biotech.

FDA clears Stone Clear, an ultrasound device aiding post-lithotripsy kidney stone fragment passage. The device, by SonoMotion, uses ultrasound propulsion to reposition fragments, reducing relapse risk by 70% compared to observation. It requires no anesthesia and is completed in 15 minutes.

The FDA granted de novo clearance to SonoMotion's Stone Clear device, which uses non-invasive ultrasound pulses to help pass kidney stone fragments post-lithotripsy. A study published in *The Journal of Urology* showed ultrasonic propulsion reduced relapse and added minimal risk compared to observation, with a 70% lower risk of relapse and 63% of patients passing fragments within 3 weeks. All adverse events were mild and self-resolving.

SonoMotion's Stone Clear™ device, cleared by the FDA, uses non-invasive ultrasound pulses to facilitate passage of kidney stone fragments post-lithotripsy, reducing relapse risk by 70%.